CMPX
NASDAQ HealthcareCompass Therapeutics, Inc. - Common Stock
Biotechnology
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
�� 市场数据
| 价格 | $6.00 |
|---|---|
| 成交量 | 3,731,736 |
| 市值 | 1.08B |
| 贝塔系数 | 1.300 |
| RSI（14日） | 63.2 |
| 200日均线 | $4.57 |
| 50日均线 | $5.70 |
| 52周最高 | $6.88 |
| 52周最低 | $1.67 |
| Forward P/E | -12.44 |
| Price / Book | 5.43 |
🎯 投资策略评分
CMPX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (77/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (19/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 CMPX in your text
粘贴任何文章、记录或帖子 — 工具将提取 CMPX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.